From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis.


Journal

Angewandte Chemie (International ed. in English)
ISSN: 1521-3773
Titre abrégé: Angew Chem Int Ed Engl
Pays: Germany
ID NLM: 0370543

Informations de publication

Date de publication:
23 08 2021
Historique:
revised: 24 06 2021
received: 10 05 2021
pubmed: 26 6 2021
medline: 4 11 2021
entrez: 25 6 2021
Statut: ppublish

Résumé

Multitarget directed ligands (MTDLs) are arising as promising tools to tackle complex diseases. The main goal of this work is to create powerful modulating agents for neurodegenerative disorders. To achieve this aim, we have combined fragments that inhibit key protein kinases involved in the main pathomolecular pathways of Alzheimer's disease (AD) such as tau aggregation, neuroinflammation and decreased neurogenesis, whilst looking for a third action in beta-secretase (BACE1), responsible of β-amyloid production. We obtained well-balanced MTDLs with in vitro activity in three different relevant targets and efficacy in two cellular models of AD. Furthermore, computational studies confirmed how these compounds accommodate adequately into the long and rather narrow BACE1 catalytic site. Finally, we employed in situ click chemistry using BACE1 as protein template as a versatile synthetic tool that allowed us to obtain further MTDLs.

Identifiants

pubmed: 34169618
doi: 10.1002/anie.202106295
pmc: PMC8457121
doi:

Substances chimiques

Amyloid beta-Peptides 0
Enzyme Inhibitors 0
Ligands 0
Neuroprotective Agents 0
Triazoles 0
Amyloid Precursor Protein Secretases EC 3.4.-
Aspartic Acid Endopeptidases EC 3.4.23.-
BACE1 protein, human EC 3.4.23.46

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19344-19354

Informations de copyright

© 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH.

Références

Front Pharmacol. 2018 Nov 15;9:1247
pubmed: 30498443
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Int J Neuropsychopharmacol. 2009 Nov;12(10):1409-19
pubmed: 19460190
Acta Neuropathol. 2013 Dec;126(6):809-27
pubmed: 24113872
Ageing Res Rev. 2013 Jan;12(1):289-309
pubmed: 22742992
Drug Discov Today. 2012 Jan;17(1-2):23-34
pubmed: 21864710
J Med Chem. 2014 Mar 27;57(6):2755-72
pubmed: 24592867
Drug Dev Res. 2020 Apr;81(2):215-231
pubmed: 31471933
Proteins. 2011 Jul;79(7):2247-59
pubmed: 21590744
Drug Discov Today. 2019 Sep;24(9):1769-1783
pubmed: 31102728
J Med Chem. 2002 Mar 14;45(6):1292-9
pubmed: 11881998
Int J Mol Sci. 2021 Mar 22;22(6):
pubmed: 33809846
Curr Med Chem. 2013;20(13):1639-45
pubmed: 23410164
J Med Chem. 2020 Mar 12;63(5):2638-2655
pubmed: 31825616
Drug Discov Today. 2017 Oct;22(10):1572-1581
pubmed: 28676407
J Med Chem. 2014 Oct 23;57(20):8576-89
pubmed: 25259726
Bioorg Med Chem Lett. 2019 Mar 15;29(6):761-777
pubmed: 30709653
J Am Chem Soc. 2004 Oct 13;126(40):12809-18
pubmed: 15469276
Front Chem. 2018 May 24;6:178
pubmed: 29881722
Med Res Rev. 2020 Jan;40(1):339-384
pubmed: 31347728
Angew Chem Int Ed Engl. 2021 Aug 23;60(35):19344-19354
pubmed: 34169618
Med Res Rev. 2017 Sep;37(5):1186-1225
pubmed: 28084618
J Med Chem. 2016 Apr 28;59(8):3732-49
pubmed: 26978477
Expert Rev Clin Pharmacol. 2011 May;4(3):293-8
pubmed: 22114774
Neural Regen Res. 2019 Mar;14(3):437-440
pubmed: 30539809
J Med Chem. 2008 Feb 14;51(3):347-72
pubmed: 18181565
BioDrugs. 2016 Jun;30(3):173-94
pubmed: 27023706
Alzheimers Dement. 2015 Jun;11(6):672-80
pubmed: 25022539
Biochemistry. 2002 Sep 10;41(36):10963-7
pubmed: 12206667
Eur J Med Chem. 2017 Sep 29;138:328-342
pubmed: 28688273
Cochrane Database Syst Rev. 2003;(4):CD002037
pubmed: 14583945
J Alzheimers Dis. 2015;45(1):75-88
pubmed: 25537011
Transl Psychiatry. 2019 Mar 28;9(1):123
pubmed: 30923322
Pharmaceutics. 2021 Jan 28;13(2):
pubmed: 33525757
Alzheimers Res Ther. 2020 May 14;12(1):58
pubmed: 32410694
J Chem Inf Model. 2017 Sep 25;57(9):2143-2151
pubmed: 28813151
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2432-2438
pubmed: 28427814
Chem Rev. 2019 Jan 23;119(2):1221-1322
pubmed: 30095897
Beilstein J Nanotechnol. 2020 Jun 4;11:866-883
pubmed: 32551212

Auteurs

Vanesa Nozal (V)

Structural and Chemical Biology Department, Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.

Alfonso García-Rubia (A)

Structural and Chemical Biology Department, Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031, Madrid, Spain.

Eva P Cuevas (EP)

Structural and Chemical Biology Department, Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.

Concepción Pérez (C)

Instituto de Química Médica-CSIC), Juan de la Cierva 3, 28006, Madrid, Spain.

Carlota Tosat-Bitrián (C)

Structural and Chemical Biology Department, Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.

Fernando Bartolomé (F)

Hospital Universitario 12 de Octubre Research Institute (imas12), Group of Neurodegenerative Diseases, Juan de la Cierva 3, 28006, Madrid, Spain.

Eva Carro (E)

Hospital Universitario 12 de Octubre Research Institute (imas12), Group of Neurodegenerative Diseases, Juan de la Cierva 3, 28006, Madrid, Spain.

David Ramírez (D)

Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Llano Subercaseaux, 2801-piso 6, Santiago, Chile.

Valle Palomo (V)

Structural and Chemical Biology Department, Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031, Madrid, Spain.

Ana Martínez (A)

Structural and Chemical Biology Department, Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH